John Maraganore, Ph.D.
Investor and Strategic Advisor
CEO of Alnylam Pharmaceuticals John Maraganore, Ph.D., has served as CEO and Director of Alnylam since 2002. Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology and cardiovascular, inflammatory, and metabolic diseases. Dr. Maraganore was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology from the University of Chicago. He is the Chair of the Board for Agios Pharmaceuticals. Dr. Maraganore is Chair of the Biotechnology Industry Organization (BIO) Board and is a member of the BIO Executive Committee.